ArticleInternational journal of chronic obstructive pulmonary disease2026
Development and External Validation of a Machine Learning Model for 90-Day Readmission in Hospitalized Older Patients with AECOPD: A Two-Center Study.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Admission Systemic Immune-Inflammation Index and 90-Day AECOPD-Related Unplanned Readmission: A Single-Center Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Short-term readmission after hospitalization for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is common in older adults, yet early risk stratification remains limited. We aimed to develop and validate a 90-day readmission model using early admission data. Methods: This retrospective two-center study used a development cohort from the Affiliated Hospital of North Sichuan Medical College and an external validation cohort from Dazhou Integrated Traditional Chinese and Western Medicine Hospital. Predictors were limited to early admission variables harmonized across sites. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were derived, with component blood counts removed to reduce collinearity. Feature selection used stability selection with Elastic Net regularization. Five models were trained and compared: multivariable logistic regression, naïve Bayes (NB), linear discriminant analysis (LDA), gradient boosting machine (GBM), and extreme gradient boosting (XGBoost). Discrimination was assessed by area under the receiver operating characteristic curve (AUC), with internal validation using bootstrap-derived optimism-corrected AUC and Brier score for overall error. Interpretability was examined with Shapley additive explanations (SHAP). Results: A total of 692 patients were included (development, n=513; external validation, n=179). Six predictors were retained: NLR, SII, D-dimer, frequent exacerbations (FE), body mass index (BMI), and albumin (ALB). No strong multicollinearity was detected (|r|<0.90; variance inflation factors (VIFs) <5). XGBoost showed the best discrimination in the development cohort (AUC=0.892) and remained stable after internal validation (optimism corrected AUC=0.864). In the external cohort, XGBoost again achieved the highest AUC (0.847) with a lower Brier score than alternative models. SHAP analyses indicated D-dimer, NLR, and FE as major contributors and suggested non-linear effects. Conclusion: Using early admission data, we developed and externally validated a 90-day readmission prediction model for older adults hospitalized with AECOPD. XGBoost showed stable performance and clinically interpretable risk patterns, supporting its potential for early risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.